

## Documents

Menke, M.N.<sup>a</sup>, Salam, A.<sup>b</sup>, Framme, C.<sup>a</sup>, Wolf, S.<sup>a</sup>

**Long-term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with ranibizumab**

(2013) *Ophthalmologica*, 229 (3), pp. 168-172. Cited 23 times.

DOI: 10.1159/000346397

<sup>a</sup> Department of Ophthalmology, Inselspital, University of Bern, CH-3010 Bern, Switzerland

<sup>b</sup> Department of Ophthalmology, Kulliyyah of Medicine, International Islamic University of Malaysia, Pahang, Malaysia

**Abstract**

Background/Aims: To investigate the long-term effects of multiple intravitreal injections (IVTs) of ranibizumab (Lucentis) on intraocular pressure (IOP) in patients with neovascular age-related macular degeneration. Methods: In 320 eyes, IOP measurements were performed at baseline prior to injection and compared with IOP measurements of the last visit. Correlations between mean IOP change and total number of IVTs, visual acuity or patient age were tested. Results: The mean IOP increase was  $0.8 \pm 3.1$  mm Hg ( $p < 0.0001$ ). Seven eyes showed final IOP values between 22 and 25 mm Hg. The mean follow-up was  $22.7 \pm 14.1$  months. No further correlations between IOP change and number of IVTs, visual acuity or patient age have been found. Conclusions: This study demonstrated a statistically significant IOP increase in patients treated with repeated injections of ranibizumab. However, IOP increase required no glaucoma treatment during the study. Therefore, repeated injections with ranibizumab can be considered safe with regard to long-term IOP changes in patients without ocular hypertension or glaucoma. Copyright © 2013 S. Karger AG, Basel.

**Author Keywords**

Age-related macular degeneration; Anti-vascular endothelial growth factor; Intraocular pressure; Ranibizumab

**Index Keywords**

ranibizumab; adult, aged, article, drug effect, female, follow up, human, intraocular pressure, long term care, major clinical study, male, retina macula degeneration, treatment duration, visual acuity, age, age related macular degeneration, Article, biomicroscopy, middle aged, optical coherence tomography, treatment outcome, very elderly, wet macular degeneration; Aged, Aged, 80 and over, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Female, Follow-Up Studies, Humans, Intraocular Pressure, Intravitreal Injections, Male, Middle Aged, Retreatment, Retrospective Studies, Tonometry, Ocular, Visual Acuity, Wet Macular Degeneration

**Chemicals/CAS**

ranibizumab, 347396-82-1; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; ranibizumab

**Tradenames**

lucentis

**References**

- **Eye Diseases Prevalence Research Group: Prevalence of age-related macular degeneration in the United States**  
(2004) *Arch Ophthalmol*, 122, pp. 564-572.
- Ferrara, N., Gerber, H.-P., LeCouter, J.  
**The biology of VEGF and its receptors**  
(2003) *Nature Medicine*, 9 (6), pp. 669-676.  
DOI 10.1038/nm0603-669
- Wolf, S.  
**Current status of anti-vascular endo-thelial growth factor therapy in Europe**  
(2008) *Jpn J Ophthalmol*, 52, pp. 433-439.
- Schmidt-Erfurth, U.M., Richard, G., Augustin, A., Aylward, W.G., Bandello, F., Corcostegui, B., Cunha-Vaz, J., Schlingemann, R.O.  
**Guidance for the treatment of neovascular age-related macular degeneration**  
(2007) *Acta Ophthalmologica Scandinavica*, 85 (5), pp. 486-494.  
DOI 10.1111/j.1755-3768.2007.00979.x

- Mitchell, P., Korobelnik, J.F., Lanzetta, P., Holz, F.G., Pruenste, C., Schmidt-Erfurth, U., Tano, Y., Wolf, S.  
**Ranibizumab (Lucentis) in neovascular age-related macular degeneration: Evidence from clinical trials**  
(2010) *Br J Ophthalmol*, 94, pp. 2-13.
- *Product Monograph: Lucentis in AMD*,  
<sup>©</sup>Novartis Pharma AG, May 2010
- Fung, A.E., Lalwani, G.A., Rosenfeld, P.J., Dubovy, S.R., Michels, S., Feuer, W.J., Puliafito, C.A., Esquiabro, M.  
**An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age related macular degeneration**  
(2007) *Am J Ophthalmol*, 143, pp. 566-583.
- Brown, D.M., Kaiser, P.K., Michels, M., Soubrane, G., Heier, J.S., Kim, R.Y., Sy, J.P., Schneider, S.  
**Ranibizumab versus verteporfin for neovascular age-related macular degeneration**  
(2006) *New England Journal of Medicine*, 355 (14), pp. 1432-1444.  
DOI 10.1056/NEJMoa062655
- Rosenfeld, P.J., Brown, D.M., Heier, J.S., Boyer, D.S., Kaiser, P.K., Chung, C.Y., Kim, R.Y.  
**Ranibizumab for neovascular age-related macular degeneration**  
(2006) *New England Journal of Medicine*, 355 (14), pp. 1419-1431.  
DOI 10.1056/NEJMoa054481
- Regillo, C.D., Brown, D.M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., Shams, N.  
**Randomized, double-masked, sham controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1**  
(2008) *Am J Ophthalmol*, 145, pp. 239-248.
- Boyer, D.S., Heier, J.S., Brown, D.M., Francom, S.F., Ianchulev, T., Rubio, R.G.  
**A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration (SAILOR)**  
(2009) *Ophthalmology*, 116, pp. 1731-1739.
- Meyer, C.H., Eter, N., Holz, F.G.  
**Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the Sustain Trial**  
(2008) *Invest Ophthalmol Vis Sci*, 49.  
SUSTAIN Study Group, E-abstract 273
- Bolz, M., Schmidt-Erfurth, U.  
*Ranibizumab EXCITE study: Exploring the value of optical coherence tomography for the management of ranibizumab therapy in age related macular degeneration*,  
8th EURETINA Congress, Vienna, May 2008
- Brown, D.M., Michels, M., Kaiser, P.K., Heier, J.S., Sy, J.P., Ianchulev, T.  
**Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study**  
(2009) *Ophthalmology*, 116, pp. 57-65.  
ANCHOR Study Group
- Gismondi, M., Salati, C., Salvétat, M.L., Zeppieri, M., Brusini, P.  
**Short term effect of intravitreal injection of ranibizumab (Lucentis) on intraocular pressure**  
(2009) *J Glaucoma*, 18, pp. 658-661.
- Mojica, G., Hariprasad, S.M., Jager, R.D., Mieler, W.F.  
**Short-term intraocular pressure trends following intravitreal injections of**

- ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration**  
(2008) *British Journal of Ophthalmology*, 92 (4), p. 584.  
DOI 10.1136/bjo.2007.126193
- Sharei, V., Hohn, F., Kohler, T., Hattenbach, L.O., Mirshahi, A.  
**Course of intraocular pressure after intravitreal injection of 0.05 ml ranibi-zumab (Lucentis)**  
(2010) *Eur J Ophthalmol*, 20, pp. 174-179.
  - Knecht, P.B., Michels, S., Sturm, V., Bosch, M.M., Menke, M.N.  
**Tunneled versus straight intra-vitreous injection: Intravitreal pressure changes, vitreous reflux and patient discomfort**  
(2009) *Retina*, 29, pp. 1175-1181.
  - Bakri, S.J., McCannel, C.A., Edwards, A.O., Moshfeghi, D.M.  
**Persistent ocular hypertension following intravitreal ranibizumab**  
(2008) *Graefes Arch Clin Exp Ophthalmol*, 246, pp. 955-958.
  - Kahook, M.Y., Kimura, A.E., Wong, L.J., Ammar, D.A., Maycotte, M.A., Mandava, N.  
**Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections**  
(2009) *Ophthalmic Surg Lasers Imaging*, 40, pp. 293-295.
  - Adelman, R.A., Zheng, Q., Mayer, H.R.  
**Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections**  
(2010) *J Ocul Pharmacol Ther*, 26, pp. 105-110.
  - Choi, D.Y., Ortube, M.C., McCannel, C.A., Sarraf, D., Hubschman, J.P., McCannel, T.A., Gorin, M.B.  
**Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibi-zumab, and pegaptanib**  
(2011) *Retina*, 31, pp. 1028-1035.
  - Tseng, J.J., Vance, S.K., Della Torre, K.E., Mendonca, L.S., Cooney, M.J., Klancnik, J.M., Sorenson, J.A., Freund, K.B.  
**Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration**  
(2012) *J Glaucoma*, 21, pp. 241-247.
  - Krohne, T.U., Eter, N., Holz, F.G., Meyer, C.H.  
**Intraocular pharmacokinetics of bevacizumab after single use intravitreal injection in humans**  
(2008) *Am J Ophthalmol*, 146, pp. 508-512.
  - Jalil, A., Fenerty, C., Charles, S.  
**Intravitreal beva-cizumab (Avastin) causing acute glaucoma: An unreported complication**  
(2007) *Eye*, 21, p. 1541.
  - Kahook, M.Y., Liu, L., Ruzycki, P., Mandava, N., Carpenter, J.F., Petrasj, J.M., Ammar, D.A.  
**Highmolecular-weight aggregates in repackaged bevacizumab**  
(2010) *Retina*, 30, pp. 887-892.
  - Liu, L., Ammar, D.A., Ross, L.A., Mandava, N., Kahook, M.Y., Carpenter, J.F.  
**Silicone oil micro-droplets and protein aggregates in repackaged bevacizumab and ranibizumab: Effects of long-term storage and product mishandling**  
(2011) *Invest Ophthalmol Vis Sci*, 52, pp. 1023-1034.

- Klein, B.E., Klein, R., Linton, K.L.  
**Intraocular pressure in an American community. the Beaver Dam Eye Study**  
(1992) *Invest Ophthalmol Vis Sci*, 33, pp. 2224-2228.
- Bonomi, L., Marchini, G., Marraffa, M., Bernardi, P., De Franco, I., Perfetri, S., Varotto, A., Tenna, V.  
**Prevalence of glaucoma and intraocular pressure distribution in a defined population: The Egna-Neumarkt study**  
(1998) *Ophthalmology*, 105 (2), pp. 209-215.  
DOI 10.1016/S0161-6420(98)92665-3
- Rochtchina, E., Mitchell, P., Wang, J.J.  
**Relationship between age and intraocular pressure: The Blue Mountains Eye Study**  
(2002) *Clinical and Experimental Ophthalmology*, 30 (3), pp. 173-175.  
DOI 10.1046/j.1442-9071.2002.00519.x
- Wu, S.-Y., Leske, M.C.  
**Associations with intraocular pressure in the Barbados Eye Study**  
(1997) *Archives of Ophthalmology*, 115 (12), pp. 1572-1576.

**Correspondence Address**

Menke M.N.; Department of Ophthalmology, , CH-3010 Bern, Switzerland; email: marcel.menke@insel.ch

**ISSN:** 00303755

**CODEN:** OPHTA

**PubMed ID:** 23548723

**Language of Original Document:** English

**Abbreviated Source Title:** Ophthalmologica

2-s2.0-84876472628

**Document Type:** Article

**Publication Stage:** Final

**Source:** Scopus

---

**ELSEVIER**

Copyright © 2024 Elsevier B.V. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

 **RELX Group™**